Press Release For Immediate Release

Glenmark announces settlement of litigation with Daiichi Sankyo & Genzyme for Colesevelam Hydrochloride

July 4, 2011 : Glenmark Pharmaceuticals Limited , Glenmark Generics Limited and Glenmark Generics Inc., USA ("Glenmark") announce the settlement of litigation with Daiichi Sankyo, Inc. and Genzyme Corporation ("Daiichi Sankyo and Genzyme") regarding Glenmark's Abbreviated New Drug Application (ANDA) filed with the U.S. Food and Drug Administration for Colesevelam Hydrochloride.

Daiichi Sankyo and Genyzme filed a patent infringement suit in November 2010 in the U.S. District Court for the District of Delaware seeking to prevent Glenmark from commercializing its ANDA prior to expiration of the Orange Book patents.

Today's announcement confirms that parties have reached a settlement agreement and Glenmark has received a license from Daiichi Sankyo and Genzyme that will permit Glenmark to launch its generic colesevelam hydrochloride products on April 2, 2015, or earlier under certain circumstances.

Daiichi Sankyo currently markets colesevelam hydrochloride as a powder for oral suspension as well as in tablet form as Welchol®[1] indicated for the treatment of primary hyperlipidemia and type 2 diabetes mellitus. Total sales as reported by IMS Health for the 12 month period ending December 2010 were approximately USD 51 million for the oral suspension and USD 327 million for the tablet.

About Glenmark Generics Limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza
Glenmark, Mumbai, India Tel: [+91 22] 40189919 Email : connect@glenmark-generics.com

[1] Welchol® is a registered trademark of Daiichi Sankyo, Inc.